prodigiosin has been researched along with Acute-Disease* in 2 studies
2 other study(ies) available for prodigiosin and Acute-Disease
| Article | Year |
|---|---|
Effective prevention of lethal acute graft-versus-host disease by combined immunosuppressive therapy with prodigiosin and cyclosporine A.
Prodigiosin (PDG), a bacterial metabolite, is a known T cell-specific immunosuppressant. Here, we compared its inhibitory potency and mode of action with cyclosporine A (CsA) in a mouse model. PDG efficiently inhibited T cell proliferation with an IC(50) of 3.37 ng/ml, a similar dose to that of CsA (IC(50) of 2.71 ng/ml). PDG inhibited only IL-2Ralpha expression, but not IL-2 expression, whereas CsA inhibited both. Exogenously added IL-2 reversed the suppressive activity of CsA, but not that of PDG. Moreover, although both PDG and CsA markedly reduced mortality rates in lethal acute graft-versus-host disease (GVHD), the combined treatment was more effective than either drug alone. These results demonstrate that PDG and CsA have similar inhibitory potencies, but different modes of action, and suggest that PDG has potential use as a supplementary immunosuppressant in combination with CsA for the treatment of GVHD. Topics: Acute Disease; Animals; Arthritis, Experimental; Bacteria; Cell Proliferation; Cyclosporine; Disease Models, Animal; Drug Administration Schedule; Drug Evaluation, Preclinical; Drug Therapy, Combination; Female; Graft vs Host Disease; Immunosuppressive Agents; Interleukin-2; Interleukin-2 Receptor alpha Subunit; Lymphocytes; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Prodigiosin; Receptors, Interleukin; T-Cell Antigen Receptor Specificity; Time Factors | 2005 |
[Prodigiosin in the overall therapy of dysentery and in the prevention of intrahospital viral respiratory infection in children].
Prodigiozan was tested in complex therapy of children with acute dysentery. Comparison of clinical symptoms, specific immunogenesis and child sanation periods from Shigella in the child groups treated (80) and non-treated (74) with prodigiozan showed that prodigiozan lowered the rate of intrahospital acute respiratory virus infection, provided more favourable dysentery progression, more tensed specific immunity and the patient clearance from Shigella. Topics: Acute Disease; Antibody Formation; Child, Preschool; Cross Infection; Dysentery, Bacillary; Humans; Infant; Prodigiosin; Respiratory Tract Infections; Shigella flexneri; Shigella sonnei; Virus Diseases | 1975 |